NICE OKs Remicade, Enbrel and Humira for psoriatic arthritis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, says that physicians can now prescribe Abbott's Humira (adalimumab), Wyeth's Enbrel (etanercept) and Merck & Co's Remicade (infliximab) for some NHS patients with psoriatic arthritis. The institute issued final guidance along these lines this week.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.